A PSEN2 test checks the presenilin 2 gene for harmful changes that cause early-onset familial Alzheimer disease. It can clarify diagnosis and family risk in the right families, but it covers a small share of cases and cannot rule out disease. Genetic tests are not routine for Alzheimer diagnosis or risk prediction. The National Institute on Aging says a specialist may order APP, PSEN1 and PSEN2 testing for early-age symptoms plus strong family history, as explained in the National Institute on Aging genetics fact sheet.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who is this test meant for?
- What can a result clarify for families?
- Why does a negative result have limits?
- What should you arrange before testing?
Who is this test meant for?
PSEN2 testing fits a narrow group, not everyone worried about memory loss. The U.S. National Library of Medicine links PSEN2 to early-onset familial disease, with at least 11 harmful variants accounting for less than 5% of early-onset cases, according to the MedlinePlus PSEN2 gene page.
Inheritance is autosomal-dominant, which means one copy from either parent can pass the risk. Joint genetics guidelines put penetrance near 95%, with typical onset from ages 40 to 75. First-degree relatives of a known carrier face about a 50% chance of inheriting the variant. A specialist usually considers testing when several clues line up:.
- symptoms starting at an unusually early age
- multiple close relatives with early-onset Alzheimer disease
- a family variant in APP, PSEN1 or PSEN2 already identified
What can a result clarify for families?
The clearest value comes when a family variant is already known. A positive result can explain early symptoms and separate inherited disease from other causes of cognitive change. It can also identify which relatives carry the same variant and which do not. That information has practical uses.
Mayo Clinic reporting notes it can inform family planning, longer-term care planning and eligibility for prevention trials. For example, a carrier may join a study for familial Alzheimer disease, while a non-carrier can focus on age-related brain health. Predictive testing works best with counseling and a clear plan for sharing results. Relatives should decide in advance how much they want to know and who will receive the news.
Why does a negative result have limits?
A negative PSEN2 result does not rule out Alzheimer disease. Most cases are late-onset or unrelated to PSEN2, and only a small fraction are early-onset familial cases. This matters because Alzheimer disease has many causes. A person can still develop late-onset disease from age, vascular risk and other genes.
A family can also carry a different inherited change in APP or PSEN1. Think of PSEN2 as one small drawer in a large cabinet. Opening it helps when the family pattern points there. When the pattern points elsewhere, an empty drawer leaves the main question open.
What should you arrange before testing?
Start with formal genetic counseling before and after testing. The Alzheimer's Association strongly recommends counseling so people can weigh treatment choices, mood and family effects, and research options, as stated in the Alzheimer's Association testing statement. Guidelines also set boundaries for family testing. They do not recommend testing children for adult-onset Alzheimer genes.
They advise against prenatal testing when the result would not change pregnancy management. Check insurance timing while you are still asymptomatic. Federal law bars health-insurance and employment discrimination based on genetic information, but it does not cover life, disability or long-term-care insurance. Ask the counselor about applications for those policies before giving a DNA sample.





